Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Escape from autologous humoral immunity of HIV-1 is not associated with a decrease in replicative capacity.

Bunnik EM, Lobbrecht MS, van Nuenen AC, Schuitemaker H.

Virology. 2010 Feb 5;397(1):224-30. doi: 10.1016/j.virol.2009.11.009. Epub 2009 Nov 27.

2.

Emergence of monoclonal antibody b12-resistant human immunodeficiency virus type 1 variants during natural infection in the absence of humoral or cellular immune pressure.

Bunnik EM, van Gils MJ, Lobbrecht MS, Pisas L, Nanlohy NM, van Baarle D, van Nuenen AC, Hessell AJ, Schuitemaker H.

J Gen Virol. 2010 May;91(Pt 5):1354-64. doi: 10.1099/vir.0.017319-0. Epub 2010 Jan 6.

PMID:
20053822
3.

Antibody neutralization and escape by HIV-1.

Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, Salazar-Gonzalez JF, Salazar MG, Kilby JM, Saag MS, Komarova NL, Nowak MA, Hahn BH, Kwong PD, Shaw GM.

Nature. 2003 Mar 20;422(6929):307-12.

PMID:
12646921
4.

Autologous neutralizing humoral immunity and evolution of the viral envelope in the course of subtype B human immunodeficiency virus type 1 infection.

Bunnik EM, Pisas L, van Nuenen AC, Schuitemaker H.

J Virol. 2008 Aug;82(16):7932-41. doi: 10.1128/JVI.00757-08. Epub 2008 Jun 4.

5.

Viremia control despite escape from a rapid and potent autologous neutralizing antibody response after therapy cessation in an HIV-1-infected individual.

Montefiori DC, Altfeld M, Lee PK, Bilska M, Zhou J, Johnston MN, Gao F, Walker BD, Rosenberg ES.

J Immunol. 2003 Apr 1;170(7):3906-14.

6.

Human immunodeficiency virus type 1 evasion of a neutralizing anti-V3 antibody involves acquisition of a potential glycosylation site in V2.

Hatada M, Yoshimura K, Harada S, Kawanami Y, Shibata J, Matsushita S.

J Gen Virol. 2010 May;91(Pt 5):1335-45. doi: 10.1099/vir.0.017426-0. Epub 2009 Dec 23.

PMID:
20032207
7.

The prolonged culture of human immunodeficiency virus type 1 in primary lymphocytes increases its sensitivity to neutralization by soluble CD4.

Pugach P, Kuhmann SE, Taylor J, Marozsan AJ, Snyder A, Ketas T, Wolinsky SM, Korber BT, Moore JP.

Virology. 2004 Mar 30;321(1):8-22.

8.

Allosteric modulation of the HIV-1 gp120-gp41 association site by adjacent gp120 variable region 1 (V1) N-glycans linked to neutralization sensitivity.

Drummer HE, Hill MK, Maerz AL, Wood S, Ramsland PA, Mak J, Poumbourios P.

PLoS Pathog. 2013;9(4):e1003218. doi: 10.1371/journal.ppat.1003218. Epub 2013 Apr 4.

9.
10.

Viral evolution in macaques coinfected with CCR5- and CXCR4-tropic SHIVs in the presence or absence of vaccine-elicited anti-CCR5 SHIV neutralizing antibodies.

Burke B, Derby NR, Kraft Z, Saunders CJ, Dai C, Llewellyn N, Zharkikh I, Vojtech L, Zhu T, Srivastava IK, Barnett SW, Stamatatos L.

Virology. 2006 Nov 25;355(2):138-51. Epub 2006 Aug 22.

11.

Evolution of human immunodeficiency virus type 2 coreceptor usage, autologous neutralization, envelope sequence and glycosylation.

Shi Y, Brandin E, Vincic E, Jansson M, Blaxhult A, Gyllensten K, Moberg L, Broström C, Fenyö EM, Albert J.

J Gen Virol. 2005 Dec;86(Pt 12):3385-96.

PMID:
16298986
12.

Kinetics of appearance of neutralizing antibodies in 12 patients with primary or recent HIV-1 infection and relationship with plasma and cellular viral loads.

Pellegrin I, Legrand E, Neau D, Bonot P, Masquelier B, Pellegrin JL, Ragnaud JM, Bernard N, Fleury HJ.

J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Apr 15;11(5):438-47.

PMID:
8605588
13.
14.

Rapid escape from preserved cross-reactive neutralizing humoral immunity without loss of viral fitness in HIV-1-infected progressors and long-term nonprogressors.

van Gils MJ, Bunnik EM, Burger JA, Jacob Y, Schweighardt B, Wrin T, Schuitemaker H.

J Virol. 2010 Apr;84(7):3576-85. doi: 10.1128/JVI.02622-09. Epub 2010 Jan 13.

15.

The role of the humoral immune response in the molecular evolution of the envelope C2, V3 and C3 regions in chronically HIV-2 infected patients.

Borrego P, Marcelino JM, Rocha C, Doroana M, Antunes F, Maltez F, Gomes P, Novo C, Barroso H, Taveira N.

Retrovirology. 2008 Sep 8;5:78. doi: 10.1186/1742-4690-5-78.

16.

Neutralizing antibody patterns and viral escape in HIV-1 non-B subtype chronically infected treatment-naive individuals.

Kelly HR, Urbanski M, Burda S, Zhong P, Konings F, Nanfack J, Tongo M, Kinge T, Achkar J, Nyambi P.

Hum Antibodies. 2005;14(3-4):89-99.

PMID:
16720979
17.

Changing sensitivity to broadly neutralizing antibodies b12, 2G12, 2F5, and 4E10 of primary subtype B human immunodeficiency virus type 1 variants in the natural course of infection.

Bunnik EM, van Gils MJ, Lobbrecht MS, Pisas L, van Nuenen AC, Schuitemaker H.

Virology. 2009 Aug 1;390(2):348-55. doi: 10.1016/j.virol.2009.05.028. Epub 2009 Jun 17.

18.

Evidence for rapid selection and deletion of HIV-1 subpopulations in vivo by V3-specific neutralizing antibody: a model of humoral-associated selection.

Nara P, Smit L, Dunlop N, Hatch W, Merges M, Waters D, Kelliher J, Krone W, Goudsmit J.

Dev Biol Stand. 1990;72:315-41.

PMID:
2282990
19.
20.

Early low-titer neutralizing antibodies impede HIV-1 replication and select for virus escape.

Bar KJ, Tsao CY, Iyer SS, Decker JM, Yang Y, Bonsignori M, Chen X, Hwang KK, Montefiori DC, Liao HX, Hraber P, Fischer W, Li H, Wang S, Sterrett S, Keele BF, Ganusov VV, Perelson AS, Korber BT, Georgiev I, McLellan JS, Pavlicek JW, Gao F, Haynes BF, Hahn BH, Kwong PD, Shaw GM.

PLoS Pathog. 2012;8(5):e1002721. doi: 10.1371/journal.ppat.1002721. Epub 2012 May 31.

Supplemental Content

Support Center